10x Genomics Financials - Benzinga

10x Genomics Inc

TXGNASDAQ

Trade with Public

Trade with Public

$85.71

1.601.9%

近くで: Sep 25, 5:00 PM EST

$85.50

-0.21-0.25%

時間外: 7:42 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

10x Genomics Financials

10x Genomics (TXG) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est

10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $600.000 million-$625.000 million to $610.000 million-$630.000 million vs $613.851 million estimate.

Benzinga Newsdesk

PRO
10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 150 percent decrease over earnings of $0.28 per share from the

Benzinga Newsdesk

PRO
10x Genomics Affirms FY2026 Sales Guidance of $600.000M-$625.000M vs $613.107M Est.

10x Genomics (NASDAQ:TXG) affirms FY2026 sales outlook from $600.000 million-$625.000 million to $600.000 million-$625.000 million vs $613.107 million estimate.

Benzinga Newsdesk

PRO
10x Genomics Q1 EPS $(0.10) Beats $(0.30) Estimate, Sales $150.843M Beat $146.355M Estimate.

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.30) by 66.67 percent. This is a 64.29 percent increase over losses of $(0.28) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

Earnings Scheduled For February 18, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved